| Status | Discontinued |
| Technology type | Medicine |
| Decision | Selected |
| Process | TA |
| ID number | 388 |
| Topic area |
|
Provisional Schedule
| Information meeting with consultees: | 25 November 2003 |
| Closing date for invited submissions / evidence submission: | 03 February 2004 |
| Final scope published: | September 2003 |
| 1st appraisal committee meeting: | 06 October 2004 |
| 2nd appraisal committee meeting: | TBC |
Project Team
| Assessment Group / Evidence Review Group: | West Midlands Health Technology Assessment Collaboration, University of Birmingham |
| Communications manager: | Tonya Gillis |
| Executive Lead: | Andrew Dillon |
| Project manager: | Cathryn Fuller |
| Technical Lead: | Elisabeth George and Sarah Garner |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 15 December 2004 |
This review has been suspended pending the outcome of the European Medicines Agency (EMEA) review of cox II inhibitors. The clarifications requested by the Committee have now been completed, so that the Committee will have a final revised Assessment Report to consider when this topic is considered again. This meeting will be scheduled after the projected date for the issuing of the EMEA recommendations on cox II inhibitors. In the meantime, the current NICE guidance (no. 27) on this health technology will continue to apply, with the caveat that rofecoxib has been withdrawn from sale by its manufacturers. |
For further information on our processes and methods, please see our CHTE processes and methods manual